Hunan Dajiaweikang Pharmaceutical IndustryLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Shengli Hu
Chief executive officer
CN¥637.9k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.3yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Massive 41% Price Jump
Oct 08
Optimistic Investors Push Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Shares Up 30% But Growth Is Lacking
May 09Market Might Still Lack Some Conviction On Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Even After 31% Share Price Boost
Mar 08CEO
Shengli Hu (50 yo)
4.3yrs
Tenure
CN¥637,900
Compensation
Ms. Shengli Hu is GM, Financial Director & Director of Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd from July 28, 2022. She was Financial Director, Board Secretary & Director of Hunan Dajiaweikang Ph...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM, Financial Director & Director | 7.3yrs | CN¥637.90k | no data | |
| Director & Deputy GM | 1.3yrs | CN¥386.60k | 0.097% CN¥ 2.0m | |
| Chairman of the Board | 4.6yrs | CN¥685.80k | 34.15% CN¥ 694.4m | |
| Director | 10.6yrs | CN¥240.00k | 9.39% CN¥ 191.0m | |
| Chairman of the Supervisory Board | 7.3yrs | no data | 0.094% CN¥ 1.9m | |
| Independent Director | 5.2yrs | CN¥160.00k | no data | |
| Independent Director | 4.3yrs | CN¥160.00k | no data | |
| Supervisor | 7.3yrs | no data | no data | |
| Employee Representative Supervisor | 10.6yrs | no data | no data | |
| Independent Director | 1.3yrs | CN¥42.60k | no data |
6.3yrs
Average Tenure
51.5yo
Average Age
Experienced Board: 301126's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 17:57 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|